“Cassava Sciences had a productive quarter with its research programs in Alzheimer’s disease,” said Remi Barbier, President & CEO . “As a result, we anticipate having top-line results for our Phase 2b study of PTI-125, our lead drug candidate for Alzheimer’s, earlier than mid-2020.”
Just keep in mind - the phase IIb data will be reported within days or a few weeks!
Just keep in mind - the phase IIb data will be reported within days or a few weeks!
Note
Stock of the year!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.